Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. Progression to CRPC after androgen ablation therapy is predominantly driven by deregulated androgen receptor (AR) signalling [1] [2] [3] . Despite the success of recently approved therapies targeting AR signalling, such as abiraterone [4] [5] [6] and secondgeneration anti-androgens including MDV3100 (also known as enzalutamide) 7, 8 , durable responses are limited, presumably owing to acquired resistance. Recently, JQ1 and I-BET762 two selective smallmolecule inhibitors that target the amino-terminal bromodomains of BRD4, have been shown to exhibit anti-proliferative effects in a range of malignancies [9] [10] [11] [12] . Here we show that AR-signalling-competent human CRPC cell lines are preferentially sensitive to bromodomain and extraterminal (BET) inhibition. BRD4 physically interacts with the N-terminal domain of AR and can be disrupted by JQ1 (refs 11, 13) . Like the direct AR antagonist MDV3100, JQ1 disrupted AR recruitment to target gene loci. By contrast with MDV3100, JQ1 functions downstream of AR, and more potently abrogated BRD4 localization to AR target loci and AR-mediated gene transcription, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity. In vivo, BET bromodomain inhibition was more efficacious than direct AR antagonism in CRPC xenograft mouse models. Taken together, these studies provide a novel epigenetic approach for the concerted blockade of oncogenic drivers in advanced prostate cancer.
The identification and therapeutic targeting of co-activators or mediators of AR transcriptional signalling should be considered as alternative strategies to treat CRPC 14 . BRD4 is a conserved member of the BET family of chromatin readers, which includes BRD2, BRD3 and BRDT. BRD4 has a critical role in transcription by RNA polymerase II (RNA Pol II) by facilitating recruitment of the positive transcription elongation factor P-TEFb 15, 16 . Similar to other BET-family proteins, BRD4 contains two conserved bromodomains, BD1 and BD2. Competitive binding of JQ1 or I-BET762 to the bromodomain pocket results in the displacement of BRD4 from active chromatin and the subsequent removal of RNA Pol II from target genes [10] [11] [12] [13] 17 . Although most cancer cells express BET-family proteins, it is not clear why only a subset of cell lines from diverse cancers responds to BET inhibitors 9, 18 . Recently, BRD4 was shown to interact with sequence-specific DNA-binding transcription factors in a gene-specific manner 19 . As the genetic and epigenetic landscape differs between tumour types, it is possible that distinct transcriptional regulators that associate with BRD4 might influence the action of BET inhibitors.
To discover new treatment options for CRPC, we treated a panel of five prostate cancer cell lines and one benign prostate cell line with JQ1, and found three of the AR-signalling positive cells to be sensitive to JQ1, although all six cell lines express high levels of its target proteins ( Fig. 1a and Extended Data Fig. 1a, b ). Next, knockdown of BRD2, 3 and 4 (Extended Data Fig. 1c ) led to significant inhibition of cell proliferation and invasion, phenocopying JQ1 treatment (Extended Data Fig. 1d, e ). Furthermore, JQ1 treatment induced G 0 -G 1 arrest, apoptosis and associated transcriptional downregulation of the anti-apoptotic protein BCL-xl (also known as BCL2L1) in AR-positive cells 13, 18 (Fig. 1b and Extended Data Fig. 1f-h ). Similar to BCL2 downregulation by the BET inhibitor I-BET151 in leukaemia 10 , a reduction in BCL-xl by JQ1 could be explained in part by the observed loss of BRD2/3/4 recruitment to its promoter region (Extended Data Fig. 1j ). Even at a relatively low 100 nanomolar (nM) concentration, long-term colony formation of AR-positive cells was severely inhibited by JQ1 (Extended Data Fig. 1k ) with no apparent effect on JQ1 target proteins (Extended Data Fig. 1l, m) .
As AR-positive cells were preferentially sensitive to JQ1, we examined whether JQ1 has an effect on AR target genes. VCaP human prostate cancer cells that harbour the TMPRSS2-ERG gene fusion and AR amplification 20 showed a dose-dependent decrease in prostate-specific antigen (PSA) and ERG at the messenger RNA and protein levels upon JQ1 treatment (Fig. 1d, e ). Similar effects were observed in LNCaP and 22RV1 prostate cancer cells (Extended Data Fig. 2a, b ). Furthermore, bortezomib did not reverse the JQ1-mediated PSA and ERG protein loss, indicating that these genes are regulated at the transcriptional level (Extended Data Fig. 2c ).
We performed microarray analysis to examine changes in global gene expression upon JQ1 treatment. Gene set enrichment analysis (GSEA) using the AR gene signature revealed significant repression of these genes in AR-positive cells ( Fig. 1f ), suggesting a role of BET proteins in ARmediated transcription. Additionally, we observed a loss of the MYCassociated gene signature in AR-positive cell lines upon JQ1-treatment (Extended Data Fig. 2d ). MYC is a known transcriptional target of BET inhibition in haematological cancers 11, 18 . Interestingly, MYC levels were attenuated by JQ1 in cells that are AR positive and sensitive to JQ1 inhibition, but not in AR-negative cells (Extended Data Fig. 2e ). Thus, high expression of MYC per se (Extended Data Fig. 1b ) does not confer sensitivity to JQ1 in prostate cancer cells. Time-course experiments with JQ1 demonstrated loss of MYC (Extended Data Fig. 2f , g) and cyclohexamide had no additional effect on MYC protein levels (Extended Data Fig. 2h , i), ruling out a post-translational mode of JQ1 action. Phenotypically, knockdown of MYC did not affect cell invasion (Extended Data Fig. 2j ), whereas JQ1 treatment inhibited invasion (Extended Data Fig. 1e ). Furthermore, exogenous expression of MYC did not result in rescue of JQ1-mediated inhibition of cell growth (Extended Data Fig. 2k, l) . Thus, although MYC levels may be repressed by JQ1 in AR-positive cells, and may have a role in proliferation, MYC does not seem to be the primary target for the antineoplastic effects of JQ1.
As BRD4 is known to engage sequence-specific DNA-binding proteins 19 , we proposed that AR may interact directly with BRD4. We performed gelfiltration chromatography and found that AR and BRD4 predominantly co-eluted in a high-molecular-weight complex ( Fig. 2a and Extended Data Fig. 3a ). Moreover, RNA Pol II, a reported target for phosphorylation by BRD4 (ref. 21) , also co-eluted in the same complex, suggestive of a large multi-protein complex composed of AR, BRD4 and RNA Pol II. Immunoprecipitation experiments further confirmed an endogenous association between AR and BRD4 ( Fig. 2b) . Additionally, we observed an interaction between AR and BRD2/3 ( Fig. 2b) , implicating a common region in BRD2, 3 and 4 proteins responsible for AR interaction. To map the region mediating this interaction, we tested the ability of different deletion variants of BRD4 to pull-down AR in 293T cells ( Fig. 2c) . A BRD4 variant containing the BD1 and BD2 domains maintained the ability to pull-down AR even at high salt concentrations ( Fig. 2d, e ). To determine whether the BD1-BD2 domains directly interact with AR, we carried out quantitative assessment of the binding affinity using the OctetRED system. We applied varying concentrations of BD1-BD2 protein to biosensors with immobilized AR and found that BRD4 interacts with AR in a concentration-dependent fashion, with an estimated dissociation constant (K d ) of 70 nM, supporting a high-affinity interaction ( Fig. 2f and Extended Data Fig. 3b , c). To fine map this interaction we created a series of Halo-tagged AR and glutathione S-transferase (GST)tagged BRD4 constructs for in vitro pull-down studies and demonstrated that the BD1, and to a lesser extent the BD2 domain, bind directly to the N-terminal domain (NTD) domain of AR, which was further mapped to a 38-amino-acid region-NTD1b-of AR ( Fig. 2g and Extended Data Fig. 3d-f ). Subsequently, we observed the disruption of BD1-AR and BD1-NTD1b interactions by JQ1 ( Fig. 2h ), as well as loss of endogenous BRD4-AR interactions (Extended Data Fig. 3g ). Together, these data indicate that BET protein inhibition leads to disruption of the AR-BRD4 interaction, which probably explains the preferential activity of JQ1 in AR-positive prostate cancer cells. The ubiquitously expressed BRD2, 3 and 4 proteins are suggested to have overlapping functions 10, 13, 22 and, consistent with this notion, we observed AR interactions with all three. Because BET inhibitors, such as JQ1 and I-BET762, have high affinity for the BD1 and BD2 domains of BRD2/3/4 proteins 10, 11, 13 , we proposed that BET inhibitors may affect genome-wide recruitment of all three BET proteins. We performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) with antibodies against BRD2/3/4 in VCaP cells treated with JQ1 or I-BET762 (Extended Data Fig. 4a ) and observed a high genome-wide overlap between BRD2, 3 and 4 (62-86% peak overlap) (Extended Data Fig. 4b , c). JQ1 or I-BET762 treatment led to a reduction in the recruitment of all three proteins to chromatin (Extended Data Fig. 4d ). Moreover, the reduced BRD2/3/4 recruitment was equally distributed for regions with or without AR (Extended Data Fig. 4e ).
Binding of androgen (dihydrotestosterone (DHT)) to AR leads to its translocation from the cytoplasm to the nucleus, where it binds to regions of DNA harbouring androgen-responsive elements (AREs) and results in subsequent recruitment of proteins involved in transcriptional activation or suppression in a gene-specific manner. BRD4 interacts with acetylated histones as well as DNA-binding transcription factors, leading to context-dependent transcriptional activation or inhibition of target genes 15, 19, 22 . As the AR-BRD4 interaction is disrupted by JQ1 ( Fig. 2) , we next explored whether AR localization is affected in a genome-wide context. We performed ChIP-seq with antibodies against AR, BRD4 and RNA Pol II in cells that were either starved, treated with DHT or DHT plus JQ1 (Extended Data Fig. 4a ). Two anti-androgens, bicalutamide and MDV3100, were included for comparison. As expected, the average ChIP-seq signal for AR was highly enriched in DHT-treated cells ( Fig. 3a and Extended Data Fig. 5a, b ). Recruitment of AR to target loci was markedly attenuated by MDV3100 and less so by bicalutamide. Interestingly, JQ1 blocked AR recruitment almost as effectively as MDV3100 ( Fig. 3a and Extended Data Fig. 5c-e ). Furthermore, we observed a corecruitment of AR and BRD4 at 2,031 sites. The strongest association was observed within promoters of AR-regulated genes (502 promoters, P 5 4 3 10 249 ), and for the highest AR peaks (1,112 sites, P 5 1 3 10 238 ) ( Fig. 3b ). Limiting our evaluation to AR and BRD4 coincident peaks, we observed that DHT-mediated AR recruitment to these loci was inhibited by MDV3100 and to a lesser extent by JQ1 ( Fig. 3c ). By contrast, JQ1 almost completely abrogated DHT-induced BRD4 recruitment to the AR-BRD4 shared loci ( Fig. 3d ). Examples of gene tracks for ARand BRD4-associated genomic regions such as enhancers and superenhancers 17 and the effects of different treatments on their levels are shown in Fig. 3e and Extended Data Fig. 5f . Corroborating the ChIPseq data, gene expression analysis in VCaP and LNCaP cells showed more efficient repression of DHT-induced AR-target genes by JQ1 than by MDV3100 or bicalutamide (Extended Data Fig. 5g , h). JQ1 treatment had a marked effect on ERG expression in VCaP cells (Fig. 1d , e and Extended Data Fig. 5h ), and we found that the attenuation of DHT-induced ERG expression by JQ1 was due to de-recruitment of RNA Pol II from the ERG gene body and reduced binding of AR and BRD4 on the TMPRSS2 promoter/enhancer (Extended Data Fig. 6a, b ). The efficient downregulation of ERG by JQ1 has important implications, 
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as the TMPRSS2-ERG gene fusion product is the oncogenic driver in 50% of prostate cancers 20, 23 . To investigate the effect of JQ1 on ERG-mediated transcription, we performed ERG ChIP-seq in cells treated with JQ1 for 12 h-a time window in which ERG protein levels are still unaffected by JQ1 (Extended Data Fig. 6c )-and observed a significant loss in the top 4% of ERG enriched peaks (Extended Data Fig. 6d ).
We next determined the functional consequences of JQ1 treatment by measuring the expression levels of select ERG target genes (Extended Data Fig. 6e , f). As expected, the ERG-activated genes were downregulated and the ERG-repressed genes were de-repressed by JQ1 (Extended Data Fig. 6g , h). To evaluate BET inhibitor repression of ERG-mediated oncogenic function in an isogenic setting, we overexpressed ERG in RWPE and PC3 cells (Extended Data Fig. 7a, b ). Treatment with JQ1 or I-BET762 led to an attenuation of ERG-mediated invasion (Extended Data Fig. 7c ) and GSEA demonstrated a significant negative enrichment for ERG target genes upon BET inhibitor treatment (Extended Data Fig. 7d ). Furthermore, we found that ERG was highly enriched on the known distal enhancer of MYC that was reduced upon JQ treatment (Extended Data Fig. 8a, b ). Likewise, ETV1 occupies the same distalenhancer region in ETV1 fusion-positive LNCaP cells 23 . Knockdown of ERG or ETV1 along with AR led to MYC downregulation, implicating MYC regulation by ETS proteins in fusion-positive prostate cancer cells (Extended Data Fig. 8c-e ). Notably, ChIP-seq analysis of AR and RNA Pol II enrichment at the MYC locus presented an interesting pattern in which DHT treatment led to increased AR and reduced RNA Pol II binding on the MYC distal enhancer and gene body, respectively, which was reinstated in the presence of MDV3100 or bicalutamide but not JQ1 (Extended Data Fig. 8f ). This observation is consistent with the concomitant reduction in MYC expression upon DHT treatment that was de-repressed in the presence of MDV3100 but not JQ1 (Extended Data Fig. 8g -i). Lack of de-repression of MYC by JQ1 in this setting could be explained by the fact that both AR and ERG are absent from the MYC distal enhancer, leading to net loss of MYC expression. These data also suggest a mechanism by which CRPC patients become resistant to anti-androgen therapy by maintaining expression of the MYC oncogene.
Next, we sought to compare the efficacy of JQ1 and MDV3100, a direct AR antagonist used clinically to treat advanced CRPC 8 . Before embarking on the in vivo experiment we tested them on VCaP cells in vitro for 8 days and observed marginal cell death by MDV3100 versus suppression of cell growth at sub-micromolar concentrations of JQ1 (Extended Data Fig. 9a ). To rule out the possibility of JQ1 being a generic anti-androgen we confirmed that JQ1 had no effect on physiological androgen-regulated processes; however, JQ1 reduced testes size in mice, as reported previously 24 (Extended Data Fig. 9b-f ). Treatment of VCaP tumour-bearing mice with JQ1 led to a significant reduction in tumour volume/weight (Fig. 4a, b and Extended Data Fig. 10a ), whereas MDV3100 had a less pronounced effect.
Recently, several studies described the pro-metastatic effects of MDV3100 in pre-clinical models 25 . To test whether MDV3100 treatment leads to spontaneous metastasis in our VCaP xenograft model, we isolated femur, liver and spleen from MDV3100-treated mice and found evidence of metastases in femur and liver (Extended Data Fig. 10b , c). By contrast, JQ1treated mice showed no evidence of metastasis (Extended Data Fig. 10c ). Taken together, these pre-clinical studies suggest that the use of MDV3100 in clinically localized prostate cancer may potentiate the formation of micro-metastases, unlike BET inhibitors. Consistent with previous reports, JQ1 and MDV3100 were both well tolerated by mice (Extended Data Fig. 10d ). Although VCaP cells were originally derived from a patient with CRPC, VCaP tumour xenografts respond to castration in mouse models. We found that JQ1 still had a growth inhibitory effect in castrationresistant VCaP tumour xenografts and observed a 50% reduction in castration-resistant tumours by JQ1-treatment ( Fig. 4c and Extended Data Fig. 10e ).
Maintenance of AR signalling is the most common resistance mechanism that patients with advanced prostate cancer develop after conventional hormonal treatments 26 . AR amplification, mutation and alternative splicing have all been suggested as potential resistance mechanisms to anti-androgen treatments 2, 27, 28 . Over half of CRPC patients have at least one of these aberrations in the AR pathway 29 . As BET inhibitors function 'downstream' of AR ( Fig. 4d ), our data indicate that these compounds may be effective in the context of AR-mediated resistance, including Xenografted mice were randomized and then received (n 5 6 per group) vehicle, 50 mg kg 21 JQ1 or 10 mg kg 21 MDV3100, as indicated, 5 days a week. Calliper measurements were taken twice a week. Mean tumour volume 6 s.e.m. is shown. b, Individual tumour weight from different treatment groups with P values is shown. c, Top, schematic illustrating the VCaP CRPC mouse xenograft experimental design. i.p., intraperitoneal. Bottom, castrated mice bearing the VCaP CRPC xenograft received vehicle (n 5 6) or 50 mg kg 21 JQ1 (n 5 7), as indicated, 5 days a week. Mean tumour volume 6 s.e.m. is shown. Statistical significance was determined by two-tailed Student's t-test. d, Schematic depicting varying mechanisms to block AR signalling in CRPC. First, abiraterone inhibits androgen biosynthesis by blocking the enzyme CYP17A1. Second, MDV3100 competitively antagonizes androgen binding to AR preventing nuclear translocation and recruitment to target gene loci. Third, JQ1 (or BET inhibitors) blocks AR and BRD2/3/4 interaction and co-recruitment to target gene loci as well as the functional activity and/or expression of ETS and MYC. WT, wild type.
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compensatory mechanisms involving related steroid hormone receptors that are also likely to require BET bromodomain function. By functioning downstream of AR, BET inhibition is less likely to be affected by acquired resistance associated with AR antagonists, including the recently identified F876L mutation of AR 30 . Although both MDV3100 and JQ1 block AR recruitment to target loci on a genome-wide scale (the 'AR cistrome'), we found that JQ1 probably has an enhanced inhibitory effect by further abrogating co-recruitment of BRD4, which is required for mobilization of the transcriptional machinery 15, 16 .
A recent study demonstrated that BET inhibition leads to preferential loss of BRD4 at super-enhancers and consequent transcriptional elongation defects 17 . These super-enhancers were often associated with key oncogenic drivers in a variety of cancers. Tumour cells are thought to become addicted to select oncogenes and hence unusually reliant on their high expression, which may explain the preferential sensitivity of BET inhibition in cancer versus normal tissues. Although MYC and its association with multiple myeloma was highlighted as a super-enhancer-dependent cancer 17 , this framework probably applies to key transcription factors involved in the development of CRPC, including AR, ETS and MYC ( Fig. 4d ). Taken together, these data indicate that clinical evaluation of BET inhibitors is warranted in CRPC, either as monotherapy or in combination with second-generation anti-androgens.
METHODS SUMMARY
Gene expression profiling was performed using the Agilent Whole Human Genome Oligo Microarray following the manufacturer's protocol. Proteins were extracted by lysing the cells in RIPA lysis buffer (Sigma) supplemented with protease inhibitor cocktail (Sigma). Immunoblotting was performed with standard protocols using polyvinylidene difluoride (PVDF) membrane (GE Healthcare), and signals were visualized with an enhanced chemiluminescence system as described by the manufacturer (GE Healthcare). The ChIP assays for BRD2, BRD3, BRD4, AR, RNA Pol II, ERG and H3K27ac with specific antibodies were performed using HighCell ChIP kit (Diagenode) following the manufacturer's protocol. All procedures involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan and conform to all regulatory standards.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell culture. VCaP prostate cancer cells were grown in DMEM with Glutamax (Gibco); LNCaP, 22RV1, DU145 and PC3 prostate cancer cell lines were grown in RPMI 1640; all were supplemented with 10% FBS (Invitrogen) in 5% CO 2 cell culture incubator. The immortalized benign prostate cell line RWPE-1 was grown in keratinocyte media with supplements (Lonza). All cell lines were tested and found to be free of mycoplasma contamination. Cell viability assay. Cells were seeded in 96-well plates at 2,000-10,000 cells per well (optimum density for growth) in a total volume of 100 ml media containing 10% FBS. Serially diluted compounds in 100 ml media were added to the cells 12 h later. After 96 h incubation, cell viability was assessed by Cell-Titer GLO (Promega). The values were normalized and IC 50 was calculated using GraphPad Prism software. For longterm colony formation assay, 10,000-50,000 cells per well were seeded in 6-well plates and treated with either 100 nM or 500 nM of JQ1 or DMSO. After 12 days, cells were fixed with methanol, stained with crystal violet and photographed. For colorimetric assays, the stained wells were treated with 500 ml 10% acetic acid and the absorbance was measured at 560 nm using a spectrophotometer. Cell cycle analysis. Cells were grown in 6-well plates and treated with varying concentrations of JQ1. For cell cycle analysis, cells were washed 48 h post-treatment with PBS and fixed in 70% ethanol overnight. The cells were washed again with PBS, stained with propidium iodide and analysed by flow cytometry. RNA interference. Forknockdownexperiments,cellswereseededin6-wellplatesand transfected with 100 nM ON-TARGETplus SMARTpool siRNA (ThemoScientific) targeting BRD2, BRD3, BRD4, MYC or non-targeting control (Non-targeting Pool, catalogue no. D-001810-10-50, using oligofectamine (Invitrogen) according to the manufacturer's instructions). The following are the catalogue numbers and the siRNA sequences: ON-TARGETplus Human BRD2_SMARTpool, catalogue no. L-004935-00-0005,targetsequences,CACGAAAGCUACAGGAUGU,GGGCCGAGU UGUGCAUAUA, CCUAAGAAGUCCAAGAAAG, GUCCUUUCCUGCCUACG UA; ON-TARGETplus Human BRD3_SMARTpool, catalogue no. L-004936-00-005, target sequences, AAUUGAACCUGCCGGAUUA, CGGCUGAUGUUCUCGAAUU, GGAGAGAUAUGUCAAGUCU, GCGAAUGUAUGCAGGACUU; ON-TARGET plus_Human BRD4_ SMARTpool, catalogue no. L-004937-00-0005, target sequences, AAACCGAGAUCAUGAUAGU, CUACACGACUACUGUGACA, AAACACAAC UCAAGCAUCG, CAGCGAAGACUCCGAAACA; and ON-TARGETplus_Human MYC_ SMARTpool, catalogue no. L-003282-00-0005. Cells were trypsinized 24 h post-transfection and used in cell proliferation and Matrigel invasion assays as well as for RNA extractions to determine the knockdown efficiency.
For AR knockdown ON-TARGETplus Human AR-_SMART pool, catalogue no. L-003400-00-0005, target sequences, GAGCGUGGACUUUCCGGAA, UCAAGGA ACUCGAUCGUAU, CGAGAGAGCUGCAUCAGUU, CAGAAAUGAUUGCA CUAUU was used at 100 nM concentration; for ERG knockdown siRNA from Dharmacon, catalogue no. D-003886-01-0050 was used; and for ETV1 knockdown a mix of ETV1 siRNA ID s4854, catalogue no. 4392420 and ETV1 siRNA ID s4855, catalogue no. 4392420 from Life Technologies were used at 100 nM concentration for transfection using oligofectamine. Cell proliferation assay. For cell proliferation assays after siRNA knockdown, 20,000 cells per well were seeded in 24-well plates (n 5 3) and cells were harvested and counted at the indicated time points by Coulter counter (Beckman Coulter).
VCaP, LNcaP and 22RV1 cells were transduced with either Ad-c-MYC (Vector Biolabs, catalogue no. 1285) or LacZ control adenoviral particles. Twenty-four hours after infection, equal number of cells were seeded in 24-well plates and treated with vehicle, JQ1 or I-BET762 at 500 nM concentration. Cells were counted at the indicated time points by Coulter Counter. Matrigel invasion assays. Twenty-four hours after infection with siRNA or 500 nM JQ1 treatment, 0.2 3 10 6 VCaP or 0.1 3 10 6 LNCaP cells were seeded in a transwell chamber pre-coated with Matrigel (BD Biosciences). Medium containing 10% FBS in the lower chamber served as chemoattractant. In the case of JQ1, 500 nM compound was added to both upper and lower chambers. After 48 h, the non-invading cells and extracellular matrix were gently removed with a cotton swab and invasive cells located on the lower side of the chamber were stained with crystal violet, air dried, photographed and counted.
PC3 and RWPE cells were treated with JQ1 or I-BET762 at 500 nM concentration along with DMSO control for 24 h before seeding 50,000 cells per well in a transwell chamber pre-coated with Matrigel along with the corresponding drugs used for treatment. Medium containing 10% FBS in the lower chamber served as chemoattractant. After 48 h, the non-invading cells and extracellular matrix were gently removed with a cotton swab and invasive cells located on the lower side of the chamber were stained with crystal violet, air dried and photographed. For colorimetric assays, the inserts were treated with 150 ml of 10% acetic acid and the absorbance measured at 560 nm using a spectrophotometer (GE Healthcare). RNA isolation and quantitative real-time PCR. Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen) and cDNA was synthesized from 1,000 ng total RNA using SuperScript III First-Strand Synthesis SuperMix (Invitrogen). qPCRs were performed in duplicate or triplicate using Taqman assays (Applied Biosystems) or standard SYBR green reagents and protocols on a StepOnePlus Real-Time PCR system (Applied Biosystems). The target mRNA expression was quantified using the DDC t method and normalized to GAPDH expression. All primers were designed using primer 3 (http://frodo.wi.mit.edu/primer3/) and synthesized by Integrated DNA Technologies. Antibodies and immunoblot analyses. Antibodies used in the immunoprecipitation (IP) and immunoblotting (IB) assays are AR IP, IB (Abcam catalogue no. ab74272); RNA Pol II IB (Abcam catalogue no. ab5408); BRD2 IB (Abnova catalogue no. PAB3245); BRD3 IB (SantaCruz catalogue no. sc-81202); BRD4 IB (Bethyl catalogue no. A301-985A); ERG IB (Epitomics catalogue no. 2805-1); MYC IB (Sigma catalogue no. M5546); PSA IB (Dako catalogue no. A0562); GST IB (GE Life Science catalogue no. 27-4577-01); Halo IP, IB (Promega catalogue no. G9281); Poly Histidine IP, IB (Sigma catalogue no. H1029); BCL-xl IB (Cell Signaling catalogue no. 2762); cPARP IB (Cell Signaling catalogue no. 9541); GAPDH (14C10) IB (Cell Signaling catalogue no. 3683 s). All antibodies were used at dilutions suggested by the manufacturers. For western blot analysis, 200 mg total protein extract was boiled in sample buffer and 10-20 mg aliquots were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membrane (GE Healthcare). The membrane was incubated for 1 h in blocking buffer (Tris-buffered saline, 0.1% Tween (TBS-T), 5% non-fat dry milk) followed by incubation overnight at 4uC with the primary antibody. After a wash with TBS-T, the blot was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody and signals were visualized by enhanced chemiluminescence system as per the manufacturer's protocol (GE Healthcare). Immunoprecipitations. For endogenous immunoprecipitation experiments, nuclear extracts were obtained from VCaP and LNCaP cells using NE-PER nuclear extraction kit (Thermo Scientific). Nuclear pellet was then lysed in IP buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1% Triton-X 100, protease inhibitor) by sonication. Nuclear lysates (0.5-1.0 mg) were pre-cleaned by incubation with protein G Dynabeads (Life Technologies) for 1 h on a rotator at 4 uC. Five micrograms of antibody was added to the pre-cleared lysates and incubated on a rotator at 4 uC overnight before the addition of protein G Dynabeads for 1 h. Beads were washed three times in IP buffer and resuspended in 40 ml of 23 loading buffer and boiled at 90 uC for 10 min for separation of the protein and beads. Samples were then analysed by SDS-PAGE and western blotting as described earlier. For endogenous competitive assays, the VCaP cells were incubated with 5 or 25 mM JQ1 for 6 h before nuclear protein extractions.
For co-immunonoprecipitation experiments in 293T cells, plasmids encoding various deletion mutants of BRD4 in pCDNA4c (Addgene) and full-length AR in pFN21 plasmid (Promega) were transfected using Fugene 6.0 HD (Roche) according to the manufacturer's instructions. Twenty-four hours after transfection, total proteins were extracted using IP buffer supplemented with protease inhibitor cocktail mix (Sigma) and the expressions of the corresponding proteins were analysed by immunoblotting. Immunoprecipitation using Halo beads followed by immunoblotting with anti-His antibody were performed as described earlier.
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Cell-free protein-protein interaction studies. In vitro protein expression was carried out by cloning the desired expression cassettes downstream of a Halo or GST tag to produce fusion proteins. Briefly, AR and its subdomains were cloned into the pFN2K vector containing N-terminal GST sequence (catalogue no. G1891, Promega); BRD4 and its subdomains were cloned into the pFN19A vector containing N-terminal Halo sequence (catalogue no. C8461, Promega). After cloning, the fusion proteins were expressed using the cell-free transcription and translation system (catalogue no. L5030, Promega) following the manufacturer's protocol. For each reaction, protein expression was confirmed by western blot.
A total of 10 ml cell-free reaction containing Halo-and GST-tag fusion proteins were incubated in PBST (0.1% Tween) at 4 uC overnight. Ten microliters of HaloLink beads (catalogue no. G931, Promega) were blocked in BSA at 4 uC overnight. After washes with PBS, the beads were mixed with AR-BRD4 mixture and incubated at room temperature for 1 h. Halolink beads were then washed with PBST four times and eluted in SDS loading buffer. Proteins were separated on SDS gel and blotted with anti-GST antibody (GE healthcare). For competitive assay, AR-BD1, NTD1b-BD1 and AR-BD2 mixture was incubated in the presence of varying doses of JQ1 compound. AR-BRD4 direct interaction assays by OctetRED. The binding affinity between AR and BRD4 was determined by biolayer interferometry technology using the OctetRED system (ForteBio). Recombinant AR protein (catalogue no. AR-8486H, Creative Biomart) was biotinylated by EZ-Link NHS-PEG4 Biotinylation Kit (catalogue no. 21329, Thermo Scientific) following the manufacturer's protocol, and any unincorporated biotin was removed from the reactions with Zeba 2 ml desalt columns. Biotinylated proteins (5 mg ml 21 ) were then incubated with super-streptavidin biosensors (catalogue no. 18-5057, ForteBio) in binding buffer (20 mM HEPES pH 7.4, 150 mM NaCl) and washed three times in binding buffer. BRD4 (BD1-BD2) protein (catalogue no. 31047, BPS Biosciences) was serially diluted in binding buffer, and the AR-BRD4 association/dissociation was monitored by OctetRED for 10 min at 25 uC. Non-specific binding was controlled by subtracting the signal obtained from AR-RNF2 interactions from that of AR-BRD4 interactions and baseline signal drift was controlled by monitoring immobilized AR without BRD4. OctetRED analysis software was used to analyse the data. Gene expression array analysis. VCaP, LNCaP, 22RV1 and DU145 cells were treated with 500 nM JQ1 for 24 h and total RNA was extracted using RNeasy Mini Kit (Qiagen) for gene expression array analysis. For anti-androgen comparative study, VCaP and LNCaP cells were grown in media containing 10% charcoal-striped serum for 48 h followed by pre-treatment with 500 nM JQ1, 10 mM MDV3100 or 25 mM bicalutamide for 6 h and stimulated with 10 nM DHT (androgen) for 18 h. Cells treated with only vehicle or 10 nM DHT served as controls. For determining the effect of BET inhibitors in isogenic ERG system, RWPE-ERG and PC3-ERG cells were treated with 500 nM JQ1 or I-BET762 for 24 h. Expression profiling was performed using the Agilent Whole Human Genome Oligo Microarray according to the manufacturer's protocol. All samples were run in technical duplicates or quadruplets against control. Over-and underexpressed gene sets were generated by filtering to include only data points that showed twofold average over-or underexpression (log ratio with P , 0.001) in all hybridizations.
GSEA was performed using the JAVA program (http://www.broadinstitute.org/ gsea) as described previously 31 .
The AR target gene signature used in GSEA analysis was generated from common upregulated genes in VCaP and LNCaP upon DHT treatment and the gene list is as follows: ABCC4, ABHD2, ACSL3, ADARB2, AF349445, AFF4, AI089002, AI207522, AI570240, AK023660, AK025360, AK055915, AK057576, AK074291, AK092594, AK093002, AK098478, AK124281, AK124426, AL533190, AL713762, ALDH1A3, AMAC1L2, ANKRD37, ANXA2, ARSG, ASRGL1, ATP10A, ATP1A1, ATP1A4, ATRNL1, AUTS2, AW029229, AW389914, AZGP1, B3GAT1, BC039021, BC041926, BC041955, BC055421, BC062780, BG462058, BG618474, BI710972, BM469851, BMPR1B, BQ017638, BQ706262, BRP44, BU567141, BU753102, BX099483, C10orf114, C14orf162, C16orf30, C18orf1, C1orf108, C1orf113, C1orf26, C20orf112, C6orf81, CA314451, CA414006, CBLL1, CCDC4, CDC14B, CDC14C, CDYL2, CEBPD, CENPN, ChGn, CHIA, CHKA, CHST2, CLDN12, CLDN14, CLDN8, CTBP1, CUTL2, CXorf9, CYP1A1, CYP2U1, DDR2, DHCR24, DKFZp761P0423, DNAJB9, DOCK11, DOCK8, EAF2, EDG7, ELL2, ELOVL5, ELOVL7, EMP1, ENDOD1, ENST00000358356, ERN1, ERRFI1, F2RL1, FAM13A1OS, FER1L3, FGD4, FKBP5, FLJ31568, FLJ39502, FRK, FZD5, GADD45G, GIPR, GREB1, GSR, HERC3, HLA-DRB3, HOMER2, HPGD, HS3ST4, HSD17B2, IFI6, IGF1, IGF1R, IL20RA, IMPAD1, INPP4B, KCNMA1, KLF15, KLK3, KLK4, KLK5, KRT18, KRT19, KRT72, LAMA1, LDLR, LIFR, LOC205251, LOC401708, LOC641467, LOC646282, LOC730498, LONRF1, LOX, LRCH1, LRIG1, LSS, MAF, MAK, MALT1, MAP1B, MAP7D1, MBOAT2, MFSD2, MICAL1, MLPH, MOGAT2, MPZL1, MTMR9, NANOGP1, NAT1, NCAPD3, NDFIP2, NDRG1, NEBL, NEK10, NFKBIA, NNMT, NR4A1, NY-REN-7, ODC1, OLAH, ORM1, ORM2, OTUD7B, PACS1, PDLIM5, PECI, PER1, PFKFB2, PGC, PHACTR3, PNPLA8, PPP2CB, RAB27A, RAB4A, RASD1, RHOU, RUNX1, S100A5, SCRG1, SGK , SHROOM3,  SLC16A6, SLC26A2, SLC26A3, SLC2A14, SLC2A3, SLC38A4, SLC41A1, SLC45A3,  SLITRK6, SMC4, SMOC1, SNAI2, SNTG2, SOCS2, SPDEF, SPDYA, SPINK5L3,  SPOCK1, SPTB, ST6GALNAC1, STEAP4, STK17B, TACC1, TBRG1, TBX15, TG,  TGFB2, TIPARP, TLOC1, TMCC3, TMPRSS2, TNFAIP3, TPD52, TRIM36,  TRIM63, TTN, TUBA3D, WIPI1, WNT7B, WWTR1 , X03757, ZBTB1, ZBTB16 and ZBTB24.
The ERG gene signature was generated by extracting twofold upregulated genes from RWPE and PC3 cells stably expressing ERG compared with respective LacZexpressing cells. GSEA was performed using this gene set on gene expression data obtained from the JQ1-and I-BET762-treated RWPE and PC3 cells. We also ran GSEA using a gene set that was not changed upon expression of ERG to exclude the possibility that treatment with JQ1 and I-BET762 may change gene expression in a non-specific fashion. All of the gene expression array data (total 48) can be found at the Gene Expression Omnibus under accession number GSE55064. ChIP and ChIP-seq. The ChIP assays for BRD2, BRD3, BRD4, AR, RNA Pol II, ERG and H3K27ac were performed using HighCell ChIP kit (Diagenode) according to the manufacturer's protocol. The antibodies used for ChIP assay are AR PG-21 (Millipore catalogue no. 06-680); RNA Pol II (Abcam catalogue no. ab5408); BRD2 (Bethyl catalogue no. A302-583A); BRD3 (Bethyl catalogue no. A302-368A); BRD4 (Bethyl catalogue no. A301-985A); H3(acetyl K27) (Abcam catalogue no. ab4729) and IgG (Diagenode). For BRD2/3/4 ChIP-seq experiments with BET inhibitors, VCaP cells were treated with 500 nM JQ1 or I-BET762 for 12 h. For AR signalling ChIPseq experiments, VCaP cells were grown in charcoal-stripped serum containing media for 48 h followed by 6 h pre-treatment with vehicle or 500 nM JQ1 or 10 mM MDV3100 or 25 mM bicalutamide and then stimulated with 10 nM DHT for 12 h. For ERG ChIP-seq studies, VCaP cells were treated with 500 nM JQ1 or vehicle for 12 h. Next, cells were crosslinked for 10 min with 1% formaldehyde. Crosslinking was terminated by the addition of 1/10 volume 1.25 M glycine for 5 min at room temperature followed by cell lysis and sonication (Bioruptor, Diagenode), resulting in an average chromatin fragment size of 200 bp. Chromatin equivalent to 5 3 10 6 cells were used for ChIP using various antibodies. ChIP DNA was isolated (IPure Kit, Diagenode) from samples by incubation with the antibody at 4 uC overnight followed by washing and reversal of crosslinking. The ChIP-seq sample preparation for sequencing was performed according to the manufacturer's instructions (Illumina). ChIP-enriched DNA samples (1-10 ng) were converted to bluntended fragments using T4 DNA polymerase, E. coli DNA polymerase I large fragment (Klenow polymerase) and T4 polynuleotide kinase (New England BioLabs (NEB)). A single A base was added to fragment ends by Klenow fragment (39 to 59 exo minus; NEB) followed by ligation of Illumina adaptors (Quick ligase, NEB). The adaptormodified DNA fragments were enriched by PCR using the Illumina Barcode primers and Phusion DNA polymerase (NEB). PCR products were size selected using 3% NuSieve agarose gels (Lonza) followed by gel extraction using QIAEX II reagents (Qiagen). Libraries were quantified with the Bioanalyzer 2100 (Agilent) and sequenced on the Illumina HiSeq 2000 Sequencer (100-nucleotide read length). ChIP-seq analysis ChIP-seq enrichment levels. ChIP enrichment levels within a peak (or site) were calculated from the sequencing data as follows. First, reads were aligned to the HG19 reference genome using Bowtie2 32 with all default settings. Second, aligned reads were sorted using NovoSort and exact duplicates were removed using Samtools 33 . Third, for each peak (site) overlapping reads were counted and this count was divided by the length of the peak or site. Fourth, to correct for differences in sequencing depth and alignment coverage the values are further normalized by the number of aligned reads per million. ChIP-seq reproducibility plots. To assess the biological variability of AR and ERG ChIP-seq experiments, we compared enrichment levels of their respective replicates. For each replicate we called peaks using MACS with all default setting against an IgG control. We excluded peaks within genomic regions prone to technical artefacts 34 . For each replicate pair we defined a set of concordant peaks as those overlapping in both replicates. For each concordant peak we calculated enrichment levels within the union of the two overlapping peaks. The scatter plots include all peaks with enrichment levels up to the 99th percentile. Overlaps of bromodomain proteins. We compared the genome-wide distribution of BRD2, BRD3 and BRD4 peaks in DMSO-treated VcaP cells. First, we called peaks for each of the proteins using MACS with all default settings and IgG control. Because we were interested in peaks that are possibly biologically significant we used a moderately stringent significance cut-off (MACS score .100). Next, we identified all genomic regions that were enriched for at least one of the proteins. Specifically, we 'reduced' all stringent peaks using GenomicRanges 35 . For each of those regions we established which of the bromodomain proteins were enriched to count the number of overlaps. Drug-induced changes of bromodomain protein enrichment levels. For each protein (BRD2, BRD3, BRD4) we assessed quantitative changes in their respective RESEARCH LETTER enrichment levels upon drug treatment (I-BET762, JQ1) relative to the levels in the DMSO control. First, peaks were called for all conditions and proteins as described earlier. Next, for each protein separately, we identified genomic regions that were enriched in any (union) of the treatment conditions (DMSO, I-BET762 or JQ1). Within those regions we quantified enrichment levels as described earlier for determining ChIP-seq enrichment levels. As enrichment levels of different proteins are not directly comparable, we normalize all enrichments to the median level of the DMSO control. Differential AR-BRD4 enrichment and AR-BRD4 overlap. HPeak, a hidden Markov model (HMM)-based peak-calling software 36 designed for the identification of protein-interactive genomic regions, was used for ChIP-seq peak determination. For enrichment plots shown in Fig. 3a, c and d , identified peaks for each sample are centred by peak summit and average coverage per million was counted within 1,500 bp relative to the peak centre. The overlap of AR-and BRD4-enriched regions were calculated by BEDtools 37 . The significance of overlap between AR and BRD4 binding was calculated using a hypergeometric test based on the derived number of associated genes. The heatmap for AR peak enrichment was generated using python-based script on raw data and visualized using JavaTreeView 38 . Differential ERG enrichment. We identified sites with significant differences in ERG levels between DMSO-and JQ1-treated cells. First we focused on concordant peaks (see ChIP-seq reproducibility plots) that were overlapping or in the 65 kb proximity of annotated gene loci. We defined a gene locus as the union of all of its known transcripts (Ensembl Genes 73). We used DESeq2 to assess the statistical significance of differences in ERG enrichment levels. Although DESeq2 was originally developed for RNA-seq, its statistical model is well-suited to count data in general. We used the tools' default multiple hypothesis correction method and report peaks with significant differences in ERG levels (adjusted P value , 0.1). To assess quantitative differences in ERG levels at significantly 'gained' (positive difference in ERG levels upon JQ1 treatment) and 'lost' (negative difference in ERG levels upon JQ1 treatment) we followed the same procedure as described earlier for determining ChIP-seq enrichment levels.
Murine prostate tumour xenograft model. Four-week-old male SCID C.B17 mice were procured from a breeding colony at University of Michigan maintained by our group. Mice were anaesthetized using 2% isoflurane (inhalation) and 2 3 10 6 VCaP prostate cancer cells suspended in 100 ml of PBS with 50% Matrigel (BD Biosciences) were implanted subcutaneously into the dorsal flank on both sides of the mice. Once the tumours reached a palpable stage (100 mm 3 ), the animals were randomized and treated with either 10 mg kg 21 body weight MDV3100 or 50 mg kg 21 body weight (doses previously used in mouse prostate cancer and multiple myeloma models 11, 39 ) by oral gavage or intraperitonially, respectively, for five days a week. Growth in tumour volume was recorded using digital callipers and tumour volumes were estimated using the formula (p/6) (L 3 W 2 ), where L is length of tumour and W is width. Loss of body weight during the course of the study was also monitored. At the end of the studies mice were killed and tumours extracted and weighed. Additionally, femur bone marrow, liver and spleen were harvested to determine spontaneous metastasis by measuring human-Alu sequence. Briefly, genomic DNA from femur bone marrow, liver and spleen were prepared using Puregene DNA purification system (Qiagen), followed by quantification of human Alu sequence by human Alu-specific Fluorogenic TaqMan qPCR probes as described previously 40, 41 . For CRPC experiment, VCaP tumourbearing mice were castrated when the tumours were approximately 200 mm 3 in size and once the tumour grew back to the pre-castration size were randomized and treated with JQ1 or vehicle (D5W) control. All procedures involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan and conform to all regulatory standards. Prostate histology and hormone measurement. Four-to-five-weeks-old male SCID C.B17 mice were administered vehicle, 10 mg kg 21 MDV3100 or 50 mg kg 21 JQ1 by oral gavage or intraperitonially, respectively, for five days a week. Highly hormone-responsive seminal vesicles attached to the prostate were harvested from mice after 4 weeks of injection. Prostate were fixed in formalin solution and processed for sectioning. Standard haematoxylin and eosin staining was performed on the formalin-fixed sections, which were used to image the different lobes of the gland. To determine testosterone levels, blood samples were collected by cardiac puncture from mice anaesthetized with isoflurane. The serum was separated from the blood and stored at 280 uC until assayed. Serum testosterone levels were measured by ligand assay at the University of Michigan-ULAM Pathology Cores for Animal Research. Xenografted mice were randomized and then received vehicle, 50 mg kg 21 JQ1 or 10 mg kg 21 MDV3100 5 days a week as indicated. Calliper measurements were taken twice a week. Individual tumour volumes from different treatment groups at the end of the experiments with P values are shown. b, MDV3100 treatment leads to spontaneous metastasis. Mice bearing VCaP xenografts (subcutaneously engrafted) treated with vehicle (n 5 6) or MDV3100 (n 5 6) were assessed for spontaneous metastasis to the femur (bone marrow) and soft tissues such as liver and spleen. Genomic DNA isolated from these sites was analysed for metastasized cells by measuring human Alu sequence (by Alu-qPCR). MDV3100-treated mice showed spontaneous metastasis to femur and liver. Spleen did not show presence of human ALU sequences. c, As in a, for mice bearing VCaP xenografts treated with vehicle (n 5 6), JQ1 (n 5 6) or MDV3100 (n 5 6). MDV3100-treated but not JQ1-treated mice showed metastasis to femur and liver. d, JQ1 or MDV3100 treatment does not affect animal weight. Mice from VCaP cell xenograft experiments treated with vehicle, 10 mg kg 21 MDV3100 or 50 mg kg 21 JQ1 were weighed at the time of calliper measurements. e, Individual tumour volume for vehicle-or JQ1-treated VCaP mouse xenograft (for data shown in Fig. 4c ). Mean 6 s.e.m. is plotted. Statistical significance was determined by two-tailed Student's t-test.
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